A Phase 2a Study Investigating the Effects of Ritlecitinib on Brainstem Auditory Evoked Potentials and Intraepidermal Nerve Fiber Histology in Adults with Alopecia Areata

    July 2024 in “ Pharmacology Research & Perspectives ”
    Samira Anderson, Guido Cavaletti, Linda J. Hood … Holly Posner
    Studysummary In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 19

    1. A Phase 2a Study Investigating the Effects of Ritlecitinib on Brainstem Auditory Evoked Potentials and Intraepidermal Nerve Fiber Histology in Adults with Alopecia Areata Pharmacology Research & Perspectives · 2024
    2. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    3. Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions Frontiers in immunology · 2023
    4. Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development Clinical Pharmacokinetics · 2023
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    7. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata Drug Design Development and Therapy · 2022
    8. Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review Dermatology and Therapy · 2021
    9. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    10. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    11. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    12. Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases Frontiers in immunology · 2019
    13. Treatment of Alopecia Areata: An Australian Expert Consensus Statement Australasian journal of dermatology · 2018
    14. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    15. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014
    16. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
    17. Hair Follicle Mesenchyme-Associated PD-L1 Regulates T-Cell Activation Induced Apoptosis: A Potential Mechanism of Immune Privilege Journal of Investigative Dermatology · 2013
    18. Interventions for Alopecia Areata Journal of Evidence-Based Medicine · 2009
    19. Interventions for Alopecia Areata Cochrane library · 2008